BSE:541096

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bharat Parenterals Limited researches, develops, manufactures, markets, sources, and distributes pharmaceutical products in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Bharat Parenterals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 541096's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.04%

541096

-1.0%

IN Pharmaceuticals

-0.4%

IN Market


1 Year Return

113.4%

541096

50.1%

IN Pharmaceuticals

2.3%

IN Market

Return vs Industry: 541096 exceeded the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: 541096 exceeded the Indian Market which returned 2.3% over the past year.


Shareholder returns

541096IndustryMarket
7 Day0.04%-1.0%-0.4%
30 Day-8.3%-0.3%3.3%
90 Day-8.5%12.8%6.7%
1 Year113.4%113.4%52.1%50.1%4.0%2.3%
3 Yearn/a29.8%26.3%0.6%-4.1%
5 Yearn/a0.5%-3.1%42.3%31.8%

Price Volatility Vs. Market

How volatile is Bharat Parenterals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bharat Parenterals undervalued compared to its fair value and its price relative to the market?

8.45x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 541096 (₹384.05) is trading above our estimate of fair value (₹57.94)

Significantly Below Fair Value: 541096 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 541096 is good value based on its PE Ratio (8.5x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 541096 is good value based on its PE Ratio (8.5x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 541096's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 541096 is good value based on its PB Ratio (1.9x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Bharat Parenterals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bharat Parenterals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bharat Parenterals performed over the past 5 years?

36.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 541096 has high quality earnings.

Growing Profit Margin: 541096's current net profit margins (11.1%) are higher than last year (8.9%).


Past Earnings Growth Analysis

Earnings Trend: 541096's earnings have grown significantly by 36.4% per year over the past 5 years.

Accelerating Growth: 541096's earnings growth over the past year (25.4%) is below its 5-year average (36.4% per year).

Earnings vs Industry: 541096 earnings growth over the past year (25.4%) exceeded the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: 541096's Return on Equity (22%) is considered high.


Next Steps

Financial Health

How is Bharat Parenterals's financial position?


Financial Position Analysis

Short Term Liabilities: 541096's short term assets (₹1.3B) exceed its short term liabilities (₹658.8M).

Long Term Liabilities: 541096's short term assets (₹1.3B) exceed its long term liabilities (₹34.2M).


Debt to Equity History and Analysis

Debt Level: 541096's debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: 541096's debt to equity ratio has reduced from 33.1% to 0.6% over the past 5 years.

Debt Coverage: 541096's debt is well covered by operating cash flow (2035.8%).

Interest Coverage: 541096's interest payments on its debt are well covered by EBIT (32.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Bharat Parenterals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 541096's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 541096's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 541096's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 541096's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 541096's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure


CEO

Bharat Desai (57 yo)

no data

Tenure

₹13,800,000

Compensation

Mr. Bharat R. Desai serves as Chairman and Managing Director of Bharat Parenterals Limited.


CEO Compensation Analysis

Compensation vs Market: Bharat's total compensation ($USD187.34K) is above average for companies of similar size in the Indian market ($USD55.70K).

Compensation vs Earnings: Bharat's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Bharat Desai
Chairman & MDno data₹13.80m13.03%
₹ 297.0m
Hemang Shah
Executive Director10.25yrs₹2.24m0.26%
₹ 6.0m
Shaileshkumar Gabhawala
Independent Directorno datano data0.16%
₹ 3.6m
Zankhana Sheth
Independent Director2.17yrsno datano data
Sanjay Shah
Non Executive Director0.75yrno datano data
Mukesh Patel
Independent Director0.75yrno datano data
Mukeshbhai Patel
Non-Executive Independent Director0.083yrno datano data

0.8yrs

Average Tenure

Experienced Board: 541096's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bharat Parenterals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bharat Parenterals Limited
  • Ticker: 541096
  • Exchange: BSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹2.280b
  • Shares outstanding: 5.73m
  • Website: https://bplindia.in

Location

  • Bharat Parenterals Limited
  • Shree Avenue
  • 1st Floor,Above Bank of Baroda
  • Vadodara
  • Gujarat
  • 390022
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
541096BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2018

Biography

Bharat Parenterals Limited researches, develops, manufactures, markets, sources, and distributes pharmaceutical products in India and internationally. It offers products in the areas of b-lactam antibiotic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 12:42
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.